Transarterial chemoembolization plus a PD‐1 inhibitor with or without lenvatinib for intermediate‐stage hepatocellular carcinoma

伦瓦提尼 医学 肝细胞癌 内科学 阶段(地层学) 肿瘤科 索拉非尼 生物 古生物学
作者
Yan‐Jun Xiang,Kang Wang,Hongming Yu,Xiaowei Li,Yuqiang Cheng,Weijun Wang,Jin‐Kai Feng,Meng‐Han Bo,Yingyi Qin,Yitao Zheng,Yunfeng Shan,Liping Zhou,Jian Zhai,Shuqun Cheng
出处
期刊:Hepatology Research [Wiley]
卷期号:52 (8): 721-729 被引量:34
标识
DOI:10.1111/hepr.13773
摘要

Transarterial chemoembolization (TACE) combined with a PD-1 inhibitor and TACE combined with a PD-1 inhibitor and lenvatinib have recently been reported as promising treatments to improve the prognosis of hepatocellular carcinoma (HCC) patients. This study aims to compare the efficacy of these two treatments.A retrospective study was conducted, and patients were recruited from two centers in China. Progression-free survival (PFS) and overall survival (OS) were compared, and the objective response rate (ORR) and disease control rate (DCR) were evaluated according to the modified Response Evaluation Criteria in Solid Tumors (mRECIST). Treatment-related adverse events (AEs) were analyzed to assess safety.The median follow-up for the entire cohort was 11.4 months. Of the 103 patients included in this study, 56 received triple therapy, and 47 received doublet therapy. PFS was significantly higher in the triple therapy group than in the doublet therapy group (mPFS 22.5 vs. 14.0 months, P < 0.001). Similar results were obtained in terms of OS (P = 0.001). The ORR and DCR were also better in the triple therapy group (64.3% vs. 38.3%, P = 0.010; 85.7% vs. 57.4%, P = 0.002). The most common AEs in the triple therapy group were decreased albumin (55.3%), decreased platelet count (51.8%) and hypertension (44.6%).The combination of TACE with a PD-1 inhibitor and lenvatinib in patients with BCLC stage B HCC might result in significantly improved clinical outcomes with a manageable safety profile compared with TACE with a PD-1 inhibitor.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
tanliulong完成签到 ,获得积分10
1秒前
1秒前
1秒前
Ushur发布了新的文献求助10
1秒前
武瑞雪完成签到,获得积分10
1秒前
2秒前
十个勤天完成签到,获得积分10
3秒前
奥特曼完成签到 ,获得积分10
6秒前
7秒前
liu完成签到,获得积分20
7秒前
8秒前
9秒前
侃侃完成签到,获得积分10
11秒前
11秒前
12秒前
万能图书馆应助安徒采纳,获得10
12秒前
13秒前
Dyson发布了新的文献求助30
13秒前
14秒前
祝您发财关注了科研通微信公众号
14秒前
陈诺发布了新的文献求助10
15秒前
徐徐诱之完成签到,获得积分10
16秒前
犹豫的蜜蜂完成签到,获得积分10
17秒前
cruise发布了新的文献求助10
17秒前
凡迪亚比应助科研通管家采纳,获得10
18秒前
yx_cheng应助科研通管家采纳,获得20
18秒前
香蕉觅云应助科研通管家采纳,获得10
18秒前
年轻馒头应助科研通管家采纳,获得20
18秒前
18秒前
Akim应助科研通管家采纳,获得10
18秒前
18秒前
彭于晏应助科研通管家采纳,获得10
18秒前
18秒前
18秒前
18秒前
威武的翠安完成签到 ,获得积分10
19秒前
科研通AI5应助如意的听云采纳,获得10
19秒前
陈诺完成签到,获得积分10
20秒前
20秒前
sunguoyi完成签到,获得积分10
20秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3975693
求助须知:如何正确求助?哪些是违规求助? 3520019
关于积分的说明 11200635
捐赠科研通 3256410
什么是DOI,文献DOI怎么找? 1798255
邀请新用户注册赠送积分活动 877490
科研通“疑难数据库(出版商)”最低求助积分说明 806390